Please assess the completion status of the following clinical trial:

Trial Title: Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>18 years of age.~* World Health Organization (WHO) Grade IV glioma with definitive resection prior to leukapheresis with residual radiographic contrast enhancement on most recent CT or MRI of \<1 cm in maximal diameter in any axial plane.~* Karnofsky Performance Status (KPS ) of \> 80% and a Curran Group status of I-IV.~Exclusion Criteria:~* Radiographic or cytologic evidence of leptomeningeal or multicentric disease at the time of enrollment.~* Prior conventional anti-tumor therapy other than steroids, RT, Avastin or TMZ.~* Pregnant or need to breast feed during the study period (Negative Beta-Human Chorionic Gonadotrophin \[HCG\] test required).~* Requirement for continuous corticosteroids above physiologic levels at time of first vaccination.~* Active infection requiring treatment or an unexplained febrile (\> 101.5o F) illness.~* Known immunosuppressive disease or human immunodeficiency virus infection.~* Patients with unstable or severe intercurrent medical conditions such as severe heart or lung disease.~* Allergic or unable to tolerate TMZ for reasons other than lymphopenia.~* Patients with previous inguinal lymph node dissection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (first randomization) (Type: EXPERIMENTAL): Patients receive CMV-ALT IV over 45-90 minutes (course 1 only) and CMV pp65-LAMP mRNA-loaded DC (CMV-DC) vaccine intradermally and administered in equal portions to each inguinal region. Vaccination repeats every 1-3 weeks for up to 3 doses in the absence of unacceptable toxicity.
- Arm II (first randomization) (Type: EXPERIMENTAL): Patients receive CMV-DC vaccine intradermally and administered in equal portions to each inguinal region. Vaccination repeats every 1-3 weeks for up to 3 doses in the absence of unacceptable toxicity.
- Arm I (second randomization) (Type: EXPERIMENTAL): Within 6 to 24 hours prior to vaccination, patients undergo skin site preparation with unpulsed DCs at the vaccination site in one inguinal region. Patients then receive indium In 111-labeled CMV-DC.
- Arm II (second randomization) (Type: EXPERIMENTAL): Within 6 to 24 hours prior to vaccination, patients undergo vaccination skin site preparation in the opposite inguinal region with tetanus toxoid. Patients then receive 111 In-labeled CMV-DC.

Based on this trial design, predict the completion outcome and termination type (if applicable).